Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | XBP1 | P17861 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.32 |
| ▸ | TPMT | P51580 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ioglycamic Acid SCHEMBL29881458 | 1.00 | TSHR (0.70) | TSHRMAPK1KMT2AKDM4EMAPT | |
| Iodipamide SCHEMBL10620456 | 0.93 | TSHR (0.84) | TSHRMAPK1KMT2AKDM4EMEN1 | |
| Iotroxic Acid SCHEMBL38038 | 0.93 | TSHR (0.65) | TSHRMAPK1KDM4EMAPTPOLB | |
| Iotetric Acid SCHEMBL37863 | 0.93 | TSHR (0.65) | TSHRMAPK1KDM4EMAPTPOLB | |
| SCHEMBL28816554 | 0.88 | MAPK1 (0.67) | TSHRMAPK1KMT2AMAPTGAA | |
| Iotrizoic Acid SCHEMBL31409209 | 0.87 | TSHR (0.58) | TSHRMAPK1KDM4EMAPTPOLB | |
| Iotrizoic Acid SCHEMBL2111608 | 0.87 | TSHR (0.58) | TSHRMAPK1KDM4EMAPTPOLB | |
| Ioglycamic Acid SCHEMBL29726597 | 0.85 | TSHR (0.51) | TSHRMAPK1KMT2AMAPTMEN1 | |
| Iotranic Acid SCHEMBL2109613 | 0.84 | TSHR (0.74) | TSHRMAPK1KMT2AMEN1POLB | |
| Iodoxamic Acid SCHEMBL377402 | 0.84 | TSHR (0.74) | TSHRMAPK1KMT2AMEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 899 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250170279-A1 | LIPOSOMAL NANOCARRIER DELIVERY SYSTEM FOR TARGETING ACTIVE CD44 MOLECULE, PREPARATION METHOD THEREFOR, AND USES THEREOF | BEIJING INNO MEDICINE CO., LTD. (CN) | 2025-05-29 | — | — | US | claimed |
| US-20250170280-A1 | LIPOSOMAL NANOCARRIER DELIVERY SYSTEM FOR TARGETING ACTIVE CD44 MOLECULE, PREPARATION METHOD THEREFOR, AND USES THEREOF | BEIJING INNO MEDICINE CO., LTD. (CN) | 2025-05-29 | — | — | US | claimed |
| WO-2021238893-A1 | EFFICIENT AND EFFECTIVE TISSUE CLEARING AGENTS AND THEIR COMPOSITIONS | THE CHINESE UNIVERSITY OF HONG KONG (CN) | 2021-12-02 | — | — | WO | claimed |
| US-20210145747-A1 | CERASOME DELIVERY SYSTEM FOR TARGETING ACTIVATED CD44 MOLECULE, PREPARATION METHOD AND USE THEREOF | BEIJING INNO MEDICINE CO., LTD. (CN) | 2021-05-20 | — | — | US | claimed |
| US-20200397926-A1 | LIPOSOMAL NANOCARRIER DELIVERY SYSTEM FOR TARGETING ACTIVE CD44 MOLECULE,PREPARATION METHOD THEREFOR, AND USES THEREOF | BEIJING INNO MEDICINE CO., LTD. (CN) | 2020-12-24 | — | — | US | claimed |
| EP-3744317-A1 | LIPOSOMAL NANOCARRIER DELIVERY SYSTEM FOR TARGETING ACTIVE CD44 MOLECULE, PREPARATION METHOD THEREFOR, AND USES THEREOF | Beijing Inno Medicine Co., Ltd. (CN) | 2020-12-02 | — | — | EP | claimed |
| EP-3610859-A1 | CERASOME DELIVERY SYSTEM FOR USE IN TARGETED ACTIVATION OF CD44 MOLECULE, PREPARATION METHOD THEREFOR AND USE | Beijing Inno Medicine Co., Ltd. (CN) | 2020-02-19 | — | — | EP | claimed |
| CN-110402137-A | A kind of silica nodule delivery system, preparation method and use for targeted activation CD44 molecule | BEIJING INNO MEDICINE CO LTD | 2019-11-01 | — | — | CN | claimed |
| EP-2706881-B1 | RADIATION PROTECTION DEVICE AND METHODS THEREOF | STEMRAD LTD (IL) | 2018-07-25 | — | — | EP | claimed |
| CN-103841848-B | Radioprotector and its method | 施特姆拉德有限公司 | 2017-12-05 | — | — | CN | claimed |
| WO-1999004824-A1 | POLYMER BASED PHARMACEUTICAL COMPOSITIONS FOR TARGETED DELIVERY OF BIOLOGICALLY ACTIVE AGENTS | SDG, INC. (US) | 1999-02-04 | — | — | WO | claimed |
| WO-1999001110-A1 | TARGETED LIPOSOMAL CONSTRUCTS FOR DIAGNOSTIC AND THERAPEUTIC USES | SDG, INC. (US) | 1999-01-14 | — | — | WO | claimed |
| CN-1189148-A | 1, 3-propane diol derivatives as bioactive compounds | SCOTIA HOLDINGS PLC (GB) | 1998-07-29 | — | — | CN | claimed |
| CN-1187813-A | Fatty acid esters as bioactive compounds | SCOTIA HOLDINGS PLC (GB) | 1998-07-15 | — | — | CN | claimed |
| US-5660814-A | Iodinated paramagnetic chelates, and their use as contrast agents | DIBRA S.P.A. (IT) | 1997-08-26 | — | — | US | claimed |
| EP-0703790-A1 | IODINATED PARAMAGNETIC CHELATES, AND THEIR USE AS CONTRAST AGENTS | BRACCO S.p.A. (IT) | 1996-04-03 | — | — | EP | claimed |
| WO-1994027644-A1 | IODINATED PARAMAGNETIC CHELATES, AND THEIR USE AS CONTRAST AGENTS | BRACCO S.P.A. (IT) | 1994-12-08 | — | — | WO | claimed |
| EP-0274467-B1 | HEPATOCYTE DIRECTED VESICLE DELIVERY SYSTEM | GEHO, W., Blair (US) | 1992-05-20 | — | — | EP | claimed |
| EP-0050457-A1 | Radiopaque cyanoacrylate compositions | BioNexus, Inc. (US) | 1982-04-28 | — | — | EP | claimed |
| US-4192859-A | MEDICAL DIAGNOSIS USING X-RAYS | E. R. SQUIBB & SONS, INC. (US) | 1980-03-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210145747-A1 | CERASOME DELIVERY SYSTEM FOR TARGETING ACTIVATED CD44 MOLECULE, PREPARATION METHOD AND USE THEREOF | CD44, LDLR, PLAUR | TSHR 3170/4885MAPK1 3939/4885KMT2A 4408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.